Who are Phentermine / Topiramate Oral Product's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/phentermine-topiramate-oral-product.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Phentermine / Topiramate Oral Product — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phentermine / Topiramate Oral Product (Phentermine / Topiramate Oral Product) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic amine / Anticonvulsant combination. Area: Obesity / Weight Management.

phase 3 Sympathomimetic amine / Anticonvulsant combination Norepinephrine release (phentermine); carbonic anhydrase inhibition and GABA modulation (topiramate) Obesity / Weight Management Small molecule Live · refreshed every 30 min

Target snapshot

Phentermine / Topiramate Oral Product (Phentermine / Topiramate Oral Product) — University of Florida. Phentermine acts as a sympathomimetic amine to suppress appetite, while topiramate enhances satiety and may increase metabolic rate through multiple mechanisms including carbonic anhydrase inhibition.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Phentermine / Topiramate Oral Product TARGET	Phentermine / Topiramate Oral Product	University of Florida	phase 3	Sympathomimetic amine / Anticonvulsant combination	Norepinephrine release (phentermine); carbonic anhydrase inhibition and GABA modulation (topiramate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic amine / Anticonvulsant combination class)

University of Florida · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Phentermine / Topiramate Oral Product — Competitive Intelligence Brief. https://druglandscape.com/ci/phentermine-topiramate-oral-product. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab